Campbell & CO Investment Adviser LLC Purchases Shares of 13,373 Lantheus Holdings, Inc. $LNTH

Key Points

• Campbell & CO Investment Adviser LLC has acquired a new position in Lantheus Holdings, purchasing 13,373 shares valued at approximately $1,305,000 during the first quarter.
• Insider Rajiv A. Patel executed a significant sale of 3,365,000 shares of Lantheus stock, resulting in a 49.18% decrease in their ownership.
• Analysts have varied opinions on Lantheus, with Truist Financial setting a price target of $63.00 and JMP Securities reducing their target from $112.00 to $73.00 while maintaining a market outperform rating.

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 13,373 shares of the medical equipment provider's stock, valued at approximately $1,305,000.

Several other large investors have also made changes to their positions in the business. State of Michigan Retirement System lifted its holdings in shares of Lantheus by 0.6% in the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after buying an additional 100 shares in the last quarter. Signaturefd LLC raised its holdings in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the period. Intrust Bank NA lifted its position in Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock worth $431,000 after buying an additional 125 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock worth $653,000 after buying an additional 139 shares during the period. Finally, Moody National Bank Trust Division increased its position in Lantheus by 1.0% during the first quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after acquiring an additional 141 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LNTH has been the topic of several analyst reports. Truist Financial set a $63.00 price target on shares of Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. JMP Securities reduced their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Insider Activity at Lantheus

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,838,066 shares of company stock valued at $384,430,031 in the last ninety days. Company insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.1%

Shares of LNTH traded down $0.60 during mid-day trading on Friday, hitting $54.90. 1,028,454 shares of the company traded hands, compared to its average volume of 2,621,779. The company has a market capitalization of $3.73 billion, a PE ratio of 14.60 and a beta of 0.14. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average of $69.20 and a 200 day moving average of $83.19. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same period in the prior year, the firm posted $1.80 EPS. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.